Clinical Trial

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of Pola-ZR2 (polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide) versus ZR2 (zanubrutinib, rituximab and lenalidomide) in the treatment of old patients with de novo diffuse large B-cell lymphoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-24.
Status change: Not Yet Recruiting → Recruiting 2024-08-02
Trial Details
NCT Number NCT06522555
Lead Sponsor Ruijin Hospital
Conditions Diffuse Large B-Cell Lymphoma
Enrollment 100 participants
Start Date 2024-07-29
Primary Completion 2028-08-10 (estimated)
Study Completion 2029-08-10 (estimated)
Updated on ClinicalTrials.gov 2024-08-05